Arovella Therapeutics FY2026 ESG Report: Carbon Offsets for Employee Flights and Governance
kalkinemedia.comArovella Therapeutics, an Australian biotech firm developing iNKT cell therapies, published its fifth annual ESG report for FY2026. The company offset all employee flight emissions, totaling 39.08 tonnes of CO2, and reported no bribery, corruption, or whistleblower incidents. Its governance framework follows ASX principles, with independent board oversight and annual risk reviews. The report notes that comprehensive emissions reporting is not material due to a small workforce and limited physical footprint. Employee air travel is the largest direct emission source, and the company achieved 100% offsetting for flights. However, indirect supplier emissions are not quantified. Arovella is currently outside Australia's mandatory climate disclosure thresholds but is monitoring regulatory changes and plans to enhance voluntary reporting as appropriate.